Asparaginyl endopeptidase (AEP) inhibitors, compositions and uses thereof

By developing asparagine endopeptidase inhibitors, especially benzo[c][1,2,5]oxadiazole derivatives, the problem of inhibiting enzyme activity has been solved, achieving therapeutic effects in blocking cancer metastasis and treating neurodegenerative diseases.

CN114340622BActive Publication Date: 2024-11-01EMORY UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080051623.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-05-24
Filing Date
2020-05-22
Publication Date
2024-11-01
Estimated Expiration
2040-05-22

AI Technical Summary

Technical Problem

Existing technologies have failed to effectively inhibit the activity of asparagine endopeptidase, leading to the occurrence and development of related diseases such as cancer, neurodegenerative diseases, and cognitive impairment.

Method used

Asparagine endopeptidase inhibitors, including benzo[c][1,2,5]oxadiazole derivatives with specific structures, have been developed to inhibit the activity of this enzyme and are formulated into pharmaceutical compositions for the treatment or prevention of related diseases.

Benefits of technology

It effectively inhibits the activity of asparagine endopeptidase, reduces cancer metastasis, improves memory, alleviates symptoms of neurodegenerative diseases, and provides neuroprotective effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114340622B_ABST
    Figure CN114340622B_ABST
Patent Text Reader

Abstract

The present disclosure relates to asparagine endopeptidase inhibitors and compositions and uses related thereto. In certain embodiments, the asparagine endopeptidase inhibitors can be used to improve memory, treat or prevent cancer, neurodegenerative diseases and cognitive disorders. In certain embodiments, the present disclosure relates to pharmaceutical compositions comprising an asparagine endopeptidase inhibitor and a pharmaceutically acceptable excipient.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 852,548, filed May 24, 2019. The entire contents of this application are hereby incorporated by reference for all purposes.

[0003] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0004] This invention was made with government support under Grant AG051538 awarded by the National Institutes of Health. The government has certain rights in this invention. Background Art

[0005] Asparagine endopeptidase (AEP), also known as legumain, is a lysosomal cysteine ​​protease that cleaves peptide bonds to asparagine residues at the C-terminus. AEP participates in various cellular events, including antigen processing, cleavage of other lysosomal enzymes, and osteoclast formation. In mammals, AEP is highly expressed in the kidney; mice lacking AEP accumulate various proteins in endosomes and lysosomes of proximal tubular cells, resulting in a pathology consisting of hyperplasia, fibrosis, and glomerular cysts. AEP null mice display symptoms similar to hemophagocytic lymphohistiocytosis, suggesting that the enzyme is involved in the pathophysiology of this disease. Biochemically, the enzyme is highly regulated by its specificity for asparagine residues and pH. Dysregulated AEP activity has been implicated in a variety of diseases, including cancer and neurodegeneration.

[0006] AEP activates MMP-2 (progelatinase A) by proteolytic removal of the N-terminal propeptide. Only limited amounts of AEP are detected in normal tissues, whereas the enzyme is overexpressed on the cell surface and in cytoplasmic vesicles of solid tumors. The endoprotease activity of AEP has been associated with increased invasiveness and aggressive behavior in several cancers, including breast, prostate, colorectal, and gastric cancers. See WO2015157376; Gawenda et al., Legumain expression as a prognostic factor in breast cancer patients, Breast Cancer Res Treat, 2007, 102, 1-6; Ohno et al., Association of legumain expression pattern with prostate cancer invasiveness and aggressiveness, World J Urol, 2013, 31, 359-364; Li et al., Effects of legumain as a potential prognostic factor on gastric cancers, Med Oncol, 2013, 30, 621; and Haugen et al., Nuclear legumain activity in colorectal cancer, PLoS One, 2013, 8, e52980.

[0007] Zhang et al. reported that amide endopeptidases are therapeutic targets for neurodegenerative diseases. Expert Opin Ther Targets, 2016, 20(10): 1237-45. See also WO2015157382.

[0008] Basurto-Islas et al. reported that activation of asparaginyl endopeptidase leads to tau hyperphosphorylation in Alzheimer's disease, J Biol Chem, 288, 2013, 17495-17507. See also Chan et al., Mice lacking asparaginyl endopeptidase develop disorders resembling hemophagocytic syndrome, Proc Natl Acad Sci USA, 2009, 106, 468-473 and Herskowitz et al., Asparaginyl endopeptidase cleaves TDP-43 in brain, Proteomics, 2012, 12, 2455-2463.

[0009] Citation of references herein is not an admission that prior art. Summary of the invention

[0010] The present disclosure relates to asparagine endopeptidase inhibitors, compositions and uses related thereto. In certain embodiments, the asparagine endopeptidase inhibitors can be used to improve memory, treat or prevent cancer, neurodegenerative diseases and cognitive disorders. In certain embodiments, the present disclosure relates to pharmaceutical compositions comprising asparagine endopeptidase inhibitors disclosed herein and pharmaceutically acceptable excipients. In certain embodiments, the present disclosure relates to methods for treating or preventing cancer or neurodegenerative diseases, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an asparagine endopeptidase inhibitor disclosed herein.

[0011] In certain embodiments, the present disclosure relates to compounds having the following Formula I:

[0012]

[0013] A prodrug, ester, derivative or salt thereof, wherein the substituents are as described herein.

[0014] In certain embodiments, the disclosure relates to a pharmaceutical composition comprising a compound as reported herein and a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a gel, a gel capsule or an emulsion. In certain embodiments, the pharmaceutical composition is in the form of a sterile pH buffered saline solution or a saline phosphate buffer or isotonic phosphate buffered saline solution having a pH of 6 to 10, optionally comprising sugar or a polysaccharide. In certain embodiments, the pharmaceutical composition is a solid form wrapped by an enteric coating. In certain embodiments, the enteric coating comprises methyl acrylate-methacrylic acid copolymer, cellulose acetate phthalate (CAP), cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate (hydroxypropyl methylcellulose acetate succinate), polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acid copolymer or a combination thereof.

[0015] In certain embodiments, the pharmaceutically acceptable excipient is selected from lactose, sucrose, mannitol, triethyl citrate, dextrose, cellulose, methylcellulose, ethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, cross-linked carboxymethyl cellulose, sodium, polyvinyl N-pyrrolidone, crospovidone, ethylcellulose, povidone, copolymers of methyl acrylate and ethyl acrylate, polyethylene glycol, sorbitan fatty acid esters, lauryl sulfate, gelatin, glycerol, monoolein, silicon dioxide, titanium dioxide, talc, corn starch, carnauba wax, stearic acid, sorbic acid, magnesium stearate, calcium stearate, castor oil, mineral oil, calcium phosphate, starch, carboxymethyl starch ether, iron oxide, triacetin, gum arabic, esters or salts thereof.

[0016] In certain embodiments, the disclosure relates to methods of treating cancer comprising administering to a subject in need thereof an effective amount of a compound as reported herein. In certain embodiments, the subject is at risk for, exhibits symptoms of, or has been diagnosed with cancer.

[0017] In certain embodiments, the disclosure relates to a method of treating or preventing cognitive impairment or memory loss, comprising administering to a subject in need thereof an effective amount of a compound as reported herein. In certain embodiments, the subject is at risk of, exhibits symptoms of, or is diagnosed with cognitive impairment.

[0018] In certain embodiments, the disclosure relates to a method of improving memory, comprising administering to a subject in need thereof an effective amount of a compound as reported herein. In certain embodiments, the subject is at risk of, exhibits symptoms of, or is diagnosed with a risk of or develops a cognitive disorder. In certain embodiments, the cognitive disorder is Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, or ALS.

[0019] In certain embodiments, the disclosure relates to methods of producing a compound as reported herein, comprising mixing starting materials with a reagent under conditions that form the compound. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1A Compounds of the present disclosure are described.

[0021] Figure 1B Shows Figure 1A Data for indicated compounds.

[0022] Figure 2A Compounds of the present disclosure are described.

[0023] Figure 2B Shows Figure 2A Data for indicated compounds.

[0024] Figure 3A Compounds of the present disclosure are described.

[0025] Figure 3B Shows Figure 3A Data for indicated compounds.

[0026] Figure 4 Explain N 2 -(5-chloro-7-morpholinobenzo[c][1,2,5]oxadiazol-4-yl)-N 5 - Preparation of methyl-1,3,4-thiadiazole-2,5-diamine.

[0027] Figure 5 Explain N 2 -Methyl-N 5 -(5-methyl-7-morpholinobenzo[c][1,2,5]oxadiazol-4-yl)-1,3,4-thiadiazole-2,5-diamine.

[0028] Figure 6 Explain N 2 -Methyl-N 5 -Synthesis of (7-morpholinylbenzo[c][1,2,5]oxadiazol-4-yl)-1,3,4-thiadiazole-2,5-diamine.

[0029] Figure 7The synthesis of the embodiments of the present disclosure is illustrated. Reagents and conditions: (a) Morpholine, K3PO4, room temperature, overnight; (b) Conc. HCl, Fe, room temperature, overnight; (c) 2-Bromo-[1,3,4]thiadiazole, PTSA, isopropanol, 80°C, overnight; (d) 2-Bromo-5-methyl-[1,3,4]thiadiazole, PTSA, isopropanol, 105°C, 24 hours; (e) 2-Chloro-5-trifluoromethyl-[1,3,4]thiadiazole, PTSA, isopropanol, 105°C, 24h.

[0030] Figure 8 The synthesis of an embodiment of the present disclosure is illustrated. Reagents and conditions: (a) HBr / Br2 / NaNO2, 0°C, overnight; (b) Compound 3 / PTSA / isopropanol, 100°C, 24h; (c) Concentrated HCl, 60°C, 2 days.

[0031] Fig. 9 The synthesis of the embodiments of the present disclosure is illustrated. Reagents and conditions: (a) morpholine, K2CO3, EtOH, room temperature; (b) NBS, CH3CN, 60°C; (c) Fe, HCl, MeOH, room temperature; (d) Boc2O, DMAP, THF, room temperature; (e) CO, TEA, MeOH, Pd(dppf)Cl2, 85°C; (f) TFA, DCM, room temperature; (g) tert-butyl (5-bromo-1,3,4-thiadiazol-2-yl)(methyl)carbamate, Pd2(dba)3, Xantphos, Cs2CO3, dioxane, 100°C; (h) DIBAL-H, DCM, -78°C; (i) TFA, DCM, room temperature.

[0032] Fig.10 The synthesis of the embodiments of the present disclosure is illustrated. Reagents and conditions: (a) Zn(CN)2, dppf, Pd2(dba)3, NMP, 100°C; (b) TFA, DCM, room temperature; (c) 5-bromo-N-methyl-1,3,4-thiadiazol-2-amine, PTSA, NMP, microwave, 150°C. DETAILED DESCRIPTION

[0033] Before describing the present disclosure in more detail, it should be understood that the present disclosure is not limited to the particular embodiments described and that it can certainly vary. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to be limiting, as the scope of the present disclosure will only be limited by the appended claims.

[0034] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, preferred methods and materials are now described.

[0035] All publications and patents cited in this specification are incorporated herein by reference, just as if each publication or patent was specifically and individually indicated to be incorporated by reference, and are incorporated herein by reference to disclose and describe the methods and / or materials related to the cited publication. The citation of any publication is for its disclosure content prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior invention. In addition, the dates of publication provided may be different from the actual publication dates, which may need to be separately confirmed.

[0036] Those skilled in the art will appreciate upon reading this disclosure that the various embodiments described and illustrated herein have discrete components and features that can be easily separated or combined with the features of any other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be performed in the order of events recited or in any other order that is logically possible.

[0037] Unless otherwise indicated, the embodiments of the present disclosure will employ techniques of medicine, organic chemistry, biochemistry, molecular biology, pharmacology, etc., which are within the skill of the art. Such techniques are fully explained in the literature.

[0038] It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0039] As used herein, the term "in combination with" when used to describe administration with other treatments means that the agent can be administered before, with, after, or in combination with the other treatments.

[0040] As used herein, the term "derivative" refers to a structurally similar compound that retains sufficient functional attributes of the identified analog. A derivative may be structurally similar because it lacks one or more atoms, is substituted, is a salt, is in a different hydration / oxidation state, or because one or more atoms within the molecule are converted, such as, but not limited to, replacing an oxygen atom with a sulfur atom or replacing an amino group with a hydroxyl group. Contemplated derivatives include converting a carbocyclic, aromatic, or phenyl ring with a heterocyclic ring, or converting a heterocyclic ring with a carbocyclic, aromatic, or phenyl ring that is generally of the same ring size. Derivatives may be prepared by any of the types of synthetic methods provided in a synthesis or organic chemistry textbook or appropriate variations, such as the methods provided in March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Wiley, 6th Edition (2007) Michael B. Smith or Domino Reactions in Organic Synthesis, Wiley (2006) Lutz F. Tietze, all of which are incorporated herein by reference.

[0041] The term "substituted" refers to a molecule in which at least one hydrogen atom is replaced by a substituent. When substituted, one or more groups are "substituents". A molecule may be multiply substituted. In the case of an oxo substituent ("=O"), two hydrogen atoms are substituted. Exemplary substituents in this case may include halogen, hydroxy, alkyl, alkoxy, nitro, cyano, oxo, carbocyclyl, carbocyclylalkyl, heterocarbocyclyl, heterocarbocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -NRaRb, -NRaC(=O)Rb, -NRaC(=O)NRaNRb, -NRaC(=O)ORb, -NRaS02Rb, -C(=O)Ra, -C(=O)ORa, -C(=O)NRaRb, -OC(=O)NRaRb, -ORa, -SRa, -SORa, -S(=O)2Ra, -OS(=O)2Ra and -S(=O)2ORa. In this case, Ra and Rb may be the same or different and are independently hydrogen, halogen, hydroxy, alkyl, alkoxy, alkyl, amino, alkylamino, dialkylamino, carbocyclyl, carbocyclylalkyl, heterocarbocyclyl, heterocarbocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl.

[0042] As used herein, "alkyl" refers to a non-cyclic straight or branched unsaturated or saturated hydrocarbon, such as those containing 1 to 10 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, etc.; while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, etc. Unsaturated alkyls contain at least one double bond or triple bond between adjacent carbon atoms (referred to as "alkenyl" or "alkynyl", respectively). Representative straight chain and branched alkenyl groups include ethenyl, propenyl, 1-butenyl, 2-butenyl, isobutenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like; while representative straight chain and branched alkynyl groups include ethynyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-butynyl, and the like.

[0043] Non-aromatic monocyclic or polycyclic alkyl groups are referred to herein as "carbocycles" or "carbocyclyl" groups. Representative saturated carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; and unsaturated carbocycles include cyclopentenyl and cyclohexenyl, and the like.

[0044] "Heterocarbocycle" or "heterocarbocyclyl" is a carbocycle containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, which may be saturated or unsaturated (but not aromatic), monocyclic or polycyclic, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. Heterocarbocycles include morpholinyl, pyrrolidonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxirane, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, etc.

[0045] "Aryl" refers to an aromatic carbocyclic monocyclic or polycyclic ring, such as phenyl or naphthyl. A polycyclic ring system may, but need not, contain one or more non-aromatic rings, as long as one of the rings is aromatic.

[0046] As used herein, "heteroaryl" or "heteroaromatic" refers to an aromatic heterocarbocyclic ring having 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur and containing at least 1 carbon atom, including monocyclic and polycyclic systems. The polycyclic system can but need not contain one or more non-aromatic rings, as long as one of the rings is an aromatic ring. Representative heteroaryl is furanyl, benzofuranyl, thienyl, benzothienyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolyl, isoquinolyl, oxazolyl, isoxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl and quinazolinyl. It is contemplated that the use of the term "heteroaryl" includes N-alkylated derivatives, such as 1-methylimidazol-5-yl substituents.

[0047] As used herein, "heterocycle" or "heterocyclic group" refers to monocyclic and polycyclic ring systems having 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur and containing at least 1 carbon atom. The monocyclic and polycyclic ring systems can be aromatic, non-aromatic or a mixture of aromatic and non-aromatic rings. Heterocycles include heterocarbocycles, heteroaryls, and the like.

[0048] "Alkylthio" refers to an alkyl group as defined above attached through a sulfur bridge. An example of an alkylthio group is methylthio (ie, -S-CH3).

[0049] "Alkoxy" refers to an alkyl group as defined above connected through an oxygen bridge. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy and sec-pentoxy. Preferred alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy.

[0050] "Alkylamino" refers to an alkyl group as defined above attached through an amino bridge. An example of an alkylamino group is methylamino (ie, -NH-CH3).

[0051] "Alkanoyl" refers to an alkyl group as defined above attached through a carbonyl bridge (ie, -(C=O)alkyl).

[0052] "Alkylsulfonyl" refers to an alkyl group as defined above attached through a sulfonyl bridge (i.e., -S(=O)2 alkyl), such as methylsulfonyl and the like, and "arylsulfonyl" refers to an aryl group attached through a sulfonyl bridge (i.e., -S(=O)2 aryl).

[0053] "Alkylsulfamoyl" refers to an alkyl group as defined above attached through a sulfamoyl bridge (ie, -S(=O)2NHalkyl), and "arylsulfamoyl" refers to an alkyl group attached through a sulfamoyl bridge (ie, -S(=O)2NHaryl).

[0054] "Alkylsulfinyl" refers to an alkyl group as defined above having the indicated number of carbon atoms attached through a sulfinyl bridge (ie, -S(=O)alkyl).

[0055] The terms "halogen" and "halo" refer to fluorine, chlorine, bromine and iodine.

[0056] The term "aroyl" refers to an aryl group (which may be optionally substituted as described above) attached to a carbonyl group (eg, -C(O)-aryl).

[0057] The term "sulfamoyl" refers to the amide of a sulfonic acid (ie, -S(=O)2NRR').

[0058] Throughout the specification, groups and substituents thereof may be chosen to provide stable moieties and compounds.

[0059] Blocking asparaginase inhibits cancer metastasis

[0060] Abnormal expression of AEP in cancer cells and on the surface of tumor-associated macrophages is associated with the involvement of the enzyme in tumor development and metastasis. Lin et al. reported that Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis. Cancer Sci, 2013, 104, 1217-1225. There is evidence that AEP is a viable drug target and a biomarker for the diagnosis and progression of various cancers. Recent studies have shown that Legumain expression may be a prognostic factor for patients with colorectal cancer, breast cancer, and ovarian cancer, as well as a potential target for tumor therapy.

[0061] Peptide-based AEP inactivators can be conjugated to nanoparticles and optionally another anticancer compound (e.g., doxorubicin) to target cancer cells and reduce systemic toxicity. AEP inhibitors can be used as targeting molecules to specifically direct anticancer drugs to cancer cells by taking advantage of the fact that AEP is expressed extracellularly on tumors and in the tumor microenvironment. Liu et al., Targeting cell surface alpha(v)beta(3)integrin increases therapeutic efficacy of a legumain protease-activated auristatin prodrug, 2012, Mol Pharm 9, 168-175 and Liao et al., Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity, Nanomedicine, 2011, 7, 665-673.

[0062] Although it is not intended that certain embodiments of the present disclosure be limited to any particular mechanism, it is possible that AEP inhibitors impart their effects by inhibiting the cleavage and activation of MMP-2. Matrix metalloproteinases are known substrates for AEP, which cleave the propeptide from the N-terminus of MMP-2, thereby enabling the enzyme to degrade the extracellular matrix and promote more aggressive and invasive tumor growth. Overexpression of MMPs is present in most human cancers and is associated with increased invasive and metastatic behavior and an overall poor prognosis, as patients who overexpress these enzymes tend to have shorter survival rates. Furthermore, in gastric cancer, enhanced expression of MMP-2 has the strongest correlation with poor prognosis compared to any other MMP.

[0063] MMP-2 cleavage in MDA-MB-231 cells and breast tissues was inhibited by AEP inhibitors in a dose-dependent manner, suggesting that AEP inhibitors successfully modulate the activity of MMP-2. Legumain can degrade fibronectin, a major component of the extracellular matrix. It is conceivable that inhibition of AEP by the inhibitors could effectively prevent thoracic and pulmonary metastasis in mice. Therefore, one way to prevent breast tumor metastasis is to prevent the activation of MMP-2 by inhibiting AEP, thereby attenuating the activity of MMP-2.

[0064] Asparaginyl endopeptidase inhibition is neuroprotective and improves cognition and memory

[0065] Aging is the biggest risk factor for Alzheimer's disease (AD). During the aging process, the pH value in the brain gradually decreases. AEP is gradually upregulated in mouse brains and activated in old mice. In addition, AEP is also elevated and activated in human AD brains compared with normal controls. Active AEP cleaves APP (amyloid precursor protein) and Tau, both of which are two major pathogenic factors in AD. AEP treatment of APP promotes BACE1 to degrade APP, resulting in upregulation of β-amyloid protein. Knockout of AEP from AD transgenic mouse models reverses pathological events in 5XFAD and APP / PS1 mice and improves cognitive deficits. On the other hand, active AEP degrades tau by proteolysis, eliminates its microtubule assembly function, induces tau aggregation, and triggers neurodegeneration. In addition, AEP is activated in tauP301s transgenic mice and human AD brains, resulting in tau truncation in NFTs. Removal of AEP from tau P301S transgenic mice significantly reduces NFT accumulation, alleviates synaptic loss, and rescues impaired hippocampal synaptic plasticity and cognitive deficits. AEP is primarily responsible for the hyperphosphorylation of tau through its cleavage SET (cleaved PP2A inhibitor), thereby inhibiting the enzyme protein phosphatase-2A (PP2A) responsible for 70% of tau phosphatase activity. AEP plays a mediating role in the development and progression of AD. Inhibition of AEP is therapeutically useful for the treatment of neurodegenerative diseases including AD.

[0066] AEP is upregulated and activated in the aging normal brain and human Alzheimer's disease (AD) brain, thus playing a key role in mediating the pathophysiology of AD. This article discloses brain-permeable and orally bioactive AEP inhibitors that reduce the formation of senile plaques in AD mouse models and alleviate cognitive deficits. High-throughput screening was performed. Several compound construction families with effective inhibitory activity were found. A non-toxic and specific AEP inhibitor was identified to selectively block AEP but not other related cysteine ​​proteases. Chronic treatment of 5XFAD mice with the inhibitor orally improved synaptic loss and enhanced long-term potentiation (LTP), thereby protecting memory loss in AD. Therefore, these findings suggest that these AEP inhibitors can be effective clinical therapeutic agents.

[0067] Stroke, seizure, and head trauma are all causes of brain ischemia, which upregulates apoptotic and necrotic processes in the brain, suggesting that they are the primary cause of neurodegeneration in humans. Deprivation of the brain of blood supply causes excitotoxic effects that lead to neuronal death through an incompletely understood mechanism. A major feature of excitotoxicity is acidosis, a phenomenon that buffers the brain interstitial pH from 7.3 to 6.0 caused by increased cellular concentrations of the excitatory amino acid glutamate. In response to the decrease in intracranial pH caused by excitoacidosis, AEP is activated and has shown abnormal activity toward one of its substrates, SET, a DNA enzyme inhibitor. SET is a phosphoprotein and is primarily localized to the nucleus, where it participates in transcriptional regulation through interaction with histone tails. SET also acts as a mediator of apoptosis by inhibiting DNA nicking in the granzyme A-mediated cell death pathway. AEP is activated after ischemia and acidosis induction and cleaves SET by proteolysis, leading to neuronal cell death; whereas SET remains intact in AEP-deficient mice, and neuronal cell death is negligible. This observation suggests that AEP inhibition offers a way to prevent neurodegeneration after stroke, epileptic seizure, or head trauma.

[0068] AEP is primarily responsible for hyperphosphorylating tau through its cleavage SET, thereby inhibiting the enzyme protein phosphatase-2A (PP2A), which is responsible for 70% of tau phosphatase activity. The levels of active AEP and N-terminal and C-terminal cleavage fragments of SET are elevated in the brains of AD patients; in addition, acidosis was found to trigger the cytoplasmic translocation of AEP and SET from lysosomes and nuclei, respectively. This finding suggests that AEP appears to play a role in the pathogenesis of Alzheimer's disease.

[0069] AD is the most common neurodegenerative disease. It is characterized by the accumulation of Aβ and insoluble tau. AEP cleaves APP and tau in AD brains. APP fragments generated by AEP are better substrates for β-secretase than full-length APP, thereby increasing Aβ production. Tau cleavage by AEP generates several fragments that can promote its accumulation. In addition, SET cleavage by AEP promotes neuronal death induced by ischemia and promotes the phosphorylation of tau. All these observations suggest that AEP inhibitors can rescue progressive neurodegeneration in AD.

[0070] Asparaginase inhibitors

[0071] The present disclosure relates to asparagine endopeptidase inhibitors. In some embodiments, the asparagine endopeptidase inhibitor is a substituted benzo[c][1,2,5]oxadiazole derivative, such as a compound of the following formula I:

[0072]

[0073] A prodrug, ester, derivative or salt thereof, wherein

[0074] X is O or S;

[0075] R 1 is optionally replaced by one or more identical or different R 10 substituted heterocyclic group;

[0076] R 10 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 10 Optionally, one or more identical or different R 11 replace;

[0077] R 11 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0078] R 2 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 2 Optionally, one or more identical or different R 20 replace;

[0079] R 20 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 20 Optionally, one or more identical or different R 21 replace;

[0080] R 21 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0081] R 3 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 3 Optionally, one or more identical or different R 30 replace;

[0082] R 30 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 30 Optionally, one or more identical or different R 31 replace;

[0083] R 31 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0084] R 4 is an amino group substituted by a heterocyclic group, the heterocyclic group being optionally substituted by one or more identical or different R 40 replace;

[0085] R 40 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 40 Optionally, one or more identical or different R 41 replace; and

[0086] R 41 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclic group, aryl group and heterocyclic group.

[0087] In certain embodiments, R 2 is hydrogen. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 4 It is a heterocyclic group.

[0088] In certain embodiments, R 4 is an amino group substituted by a five-membered heterocyclic group, the five-membered heterocyclic group being optionally substituted by one or more R 40 replace.

[0089] In certain embodiments, R 4 is amino substituted by 1,3,4-thiadiazol-2-yl, wherein the 1,3,4-thiadiazol-2-yl is optionally substituted by one or more R 40 replace.

[0090] In certain embodiments, R 1 It is morpholinyl, piperidinyl, piperazinyl or 4-alkylpiperazinyl.

[0091] In certain embodiments, the compound is 5-((7-morpholinylbenzo[c][1,2,5]oxadiazol-4-yl)amino)-1,3,4-thiadiazole-2-thiol or a salt thereof optionally substituted with one or more substituents.

[0092] In certain embodiments, the compound is N2-methyl-N5-(7-morpholinylbenzo[c][1,2,5]oxadiazol-4-yl)-1,3,4-thiadiazole-2,5-diamine or a salt thereof, optionally substituted with one or more substituents.

[0093] In certain embodiments, the compound is (7-((5-(methylamino)-1,3,4-thiadiazol-2-yl)amino)-4-morpholinylbenzo[c][1,2,5]oxadiazol-5-yl)methanol or a salt thereof optionally substituted with one or more substituents.

[0094] In certain embodiments, the present disclosure relates to compounds having the following Formula I:

[0095]

[0096]

[0097] A prodrug, ester, derivative or salt thereof, wherein the substituents are as described herein. In certain embodiments, R 4 is an amino group substituted by a five-membered heterocyclic group, the five-membered heterocyclic group being optionally substituted by one or more R 40 In certain embodiments, R 4 is amino substituted by 1,3,4-thiadiazol-2-yl, wherein the 1,3,4-thiadiazol-2-yl is optionally substituted by one or more R 40 In certain embodiments, R 1 is morpholinyl, piperidinyl, piperazinyl or 4-alkylpiperazinyl. In certain embodiments, X is oxygen. In certain embodiments, R 2 and R 3 Individually and independently is hydrogen or alkyl optionally substituted with one or more substituents.

[0098] In certain embodiments, the present disclosure relates to compounds of Formula IA:

[0099]

[0100] A prodrug, ester, derivative or salt thereof, wherein

[0101] Q is O, S, CH2 or NR 6 ;

[0102] R 3is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 3 Optionally, one or more identical or different R 30 replace;

[0103] R 30 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 30 Optionally, one or more identical or different R 31 replace;

[0104] R 31 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0105] R 4 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 4 Optionally, one or more identical or different R 40 replace;

[0106] R 40 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 40 Optionally, one or more identical or different R 41 replace;

[0107] R 41 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0108] R 6 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 6 Optionally, one or more identical or different R 60 replace;

[0109] R 60 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 60 Optionally, one or more identical or different R 61 replace;

[0110] R 61 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0111] R 7 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 7 Optionally, one or more identical or different R 70 replace;

[0112] R 70 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 70 Optionally, one or more identical or different R 71 replace; and

[0113] R 71 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclic group, aryl group and heterocyclic group.

[0114] In certain embodiments, R 4 is an amino group substituted by a five-membered heterocyclic group, the five-membered heterocyclic group being optionally substituted by one or more R 40 In certain embodiments, R 4 is amino substituted by 1,3,4-thiadiazol-2-yl, wherein the 1,3,4-thiadiazol-2-yl is optionally substituted by one or more R 40 replace.

[0115] In certain embodiments, the present disclosure relates to compounds of the following Formula IB:

[0116]

[0117] A prodrug, ester, derivative or salt thereof, wherein

[0118] Q is O, S, CH2 or NR6 ;

[0119] R 1 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 1 Optionally, one or more identical or different R 10 replace;

[0120] R 10 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 10 Optionally, one or more identical or different R 11 replace;

[0121] R 11 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0122] R 3 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 3 Optionally, one or more identical or different R 30 replace;

[0123] R 30 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R30 Optionally, one or more identical or different R 31 replace;

[0124] R 31 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0125] R 5 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 5 Optionally, one or more identical or different R 50 replace;

[0126] R 50 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 50 Optionally, one or more identical or different R 51 replace;

[0127] R 51is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0128] R 7 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 7 Optionally, one or more identical or different R 70 replace;

[0129] R 70 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 70 Optionally, one or more identical or different R 71 replace;

[0130] and

[0131] R 71 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclic group, aryl group and heterocyclic group.

[0132] In certain embodiments, the present disclosure relates to compounds of the following Formula II:

[0133]

[0134] A prodrug, ester, derivative or salt thereof, wherein

[0135] U is N or CH;

[0136] V is N or CR 2 ;

[0137] W is N or CR 3 ;

[0138] X is O or S;

[0139] Y is O, S or NH;

[0140] Z is N or CH;

[0141] R 1 is optionally replaced by one or more identical or different R 10 substituted heterocyclic group;

[0142] R 10 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 10 Optionally, one or more identical or different R 11 replace;

[0143] R 11 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0144] R 2is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 2 Optionally, one or more identical or different R 20 replace;

[0145] R 20 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 20 Optionally, one or more identical or different R 21 replace;

[0146] R 21 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0147] R 3 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 3 Optionally, one or more identical or different R 30 replace;

[0148] R 30 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 30 Optionally, one or more identical or different R 31 replace;

[0149] R 31 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0150] R 5 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 5 Optionally, one or more identical or different R 50 replace;

[0151] R 50 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 50 Optionally, one or more identical or different R 51 replace; and

[0152] R 51 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclic group, aryl group and heterocyclic group.

[0153] In certain embodiments, the present disclosure relates to compounds of the following Formula II:

[0154]

[0155] A prodrug, ester, derivative or salt thereof, wherein the substituents are as described herein. In certain embodiments, R 5 is thiol, halogen, alkyl or aminoalkyl, optionally substituted with one or more substituents. 5 is aminoalkyl. In certain embodiments, X is oxygen. In certain embodiments, V and W are CH, optionally substituted with one or more substituents. In certain embodiments, R 1 In some embodiments, Y is sulfur and Z and U are nitrogen. In some embodiments, the compound is 5-((7-morpholinylbenzo[c][1,2,5]oxadiazole-4-yl)amino)-1,3,4-thiadiazole-2-thiol or a salt thereof optionally substituted with one or more substituents.

[0156] In certain embodiments, the present disclosure relates to compounds of Formula IIA below:

[0157]

[0158] A prodrug, ester, derivative or salt thereof, wherein

[0159] U is N or CH;

[0160] Q is O, S, CH2 or NR 6 ;

[0161] X is O or S;

[0162] Y is O, S or NH;

[0163] Z is N or CH;

[0164] R 2 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 2 Optionally, one or more identical or different R 20 replace;

[0165] R 20is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 20 Optionally, one or more identical or different R 21 replace;

[0166] R 21 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0167] R 3 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 3 Optionally, one or more identical or different R 30 replace;

[0168] R 30 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 30 Optionally, one or more identical or different R 31 replace;

[0169] R 31is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0170] R 5 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 5 Optionally, one or more identical or different R 50 replace;

[0171] R 50 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 50 Optionally, one or more identical or different R 51 replace;

[0172] R 51 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0173] R 6is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 6 Optionally, one or more identical or different R 60 replace;

[0174] R 60 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 60 Optionally, one or more identical or different R 61 replace; and

[0175] R 61 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclic group, aryl group and heterocyclic group.

[0176] In certain embodiments, the present disclosure relates to compounds of the following Formula IIB:

[0177]

[0178] A prodrug, ester, derivative or salt thereof, wherein

[0179] Q is O, S, CH2 or NR 6 ;

[0180] R 2 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 2 Optionally, one or more identical or different R 20 replace;

[0181] R 20 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 20 Optionally, one or more identical or different R 21 replace;

[0182] R 21 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0183] R 3 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 3 Optionally, one or more identical or different R 30 replace;

[0184] R 30 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 30 Optionally, one or more identical or different R 31 replace;

[0185] R 31is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0186] R 5 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 5 Optionally, one or more identical or different R 50 replace;

[0187] R 50 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 50 Optionally, one or more identical or different R 51 replace;

[0188] R 51 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0189] R 6is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 6 Optionally, one or more identical or different R 60 replace;

[0190] R 60 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 60 Optionally, one or more identical or different R 61 replace; and

[0191] R 61 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclic group, aryl group and heterocyclic group.

[0192] In certain embodiments, the present disclosure relates to compounds of the following Formula IIC:

[0193]

[0194] A prodrug, ester, derivative or salt thereof, wherein

[0195] Q is O, S, CH2 or NR 6 ;

[0196] R 3 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 3 Optionally, one or more identical or different R 30 replace;

[0197] R 30 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 30 Optionally, one or more identical or different R 31 replace;

[0198] R 31 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0199] R 5 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 5 Optionally, one or more identical or different R 50 replace;

[0200] R 50 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 50 Optionally, one or more identical or different R 51 replace;

[0201] R 51is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0202] R 6 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 6 Optionally, one or more identical or different R 60 replace;

[0203] R 60 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 60 Optionally, one or more identical or different R 61 replace;

[0204] R 61 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0205] R 7is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 7 Optionally, one or more identical or different R 70 replace;

[0206] R 70 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 70 Optionally, one or more identical or different R 71 replace; and

[0207] R 71 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclic group, aryl group and heterocyclic group.

[0208] In certain embodiments, the present disclosure relates to compounds of the following formula III:

[0209]

[0210] A prodrug, ester, derivative or salt thereof, wherein

[0211] Q is individually and independently at each occurrence O, S, CH2 or NR 6 ;

[0212] X is N or CH;

[0213] V is N or CR 2 ;

[0214] W is N or CR 3 ;

[0215] R 2is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 2 Optionally, one or more identical or different R 20 replace;

[0216] R 20 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 20 Optionally, one or more identical or different R 21 replace;

[0217] R 21 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0218] R 3 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 3 Optionally, one or more identical or different R 30 replace;

[0219] R 30 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 30 Optionally, one or more identical or different R 31 replace;

[0220] R 31 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0221] R 4 is optionally replaced by one or more identical or different R 40 Substituted amino groups;

[0222] R 40 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 40 Optionally, one or more identical or different R 41 replace;

[0223] R 41 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0224] R 6is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 6 Optionally, one or more identical or different R 60 replace;

[0225] R 60 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 60 Optionally, one or more identical or different R 61 replace; and

[0226] R 61 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclic group, aryl group and heterocyclic group.

[0227] In certain embodiments, the present disclosure relates to compounds having the following Formula III:

[0228]

[0229] or a prodrug, ester, derivative or salt thereof, wherein the substituents are as described herein. In certain embodiments, Q is O. In certain embodiments, R 4 is amino. In certain embodiments, X, V and W are CH. In certain embodiments, the compound is 2,4-dimorpholinoaniline or a salt thereof optionally substituted with one or more substituents.

[0230] In certain embodiments, the present disclosure relates to compounds of the following formula IV:

[0231]

[0232] A prodrug, ester, derivative or salt thereof, wherein

[0233] Q is individually and independently at each occurrence O, S, CH2 or NR 6 ;

[0234] U is N or CH;

[0235] V is N or CR 2 ;

[0236] W is N or CR 3 ;

[0237] X is N or CH;

[0238] Y is O, S or NH;

[0239] Z is N or CH;

[0240] R 2 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 2 Optionally, one or more identical or different R 20 replace;

[0241] R 20 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 20 Optionally, one or more identical or different R 21 replace;

[0242] R 21 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0243] R 3 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 3 Optionally, one or more identical or different R 30 replace;

[0244] R 30 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 30 Optionally, one or more identical or different R 31 replace;

[0245] R 31 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0246] R 5 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 5 Optionally, one or more identical or different R 50 replace;

[0247] R 50 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 50 Optionally, one or more identical or different R 51replace;

[0248] R 51 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl and heterocyclyl;

[0249] R 6 is selected from hydrogen, alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 6 Optionally, one or more identical or different R 60 replace;

[0250] R 60 is selected from the group consisting of alkyl, alkenyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxyl, carbamoyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclic, aryl and heterocyclic, wherein R 60 Optionally, one or more identical or different R 61 replace; and

[0251] R 61 is selected from halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxyl, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, propyl, tert-butyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclic group, aryl group and heterocyclic group.

[0252] In certain embodiments, the present disclosure relates to compounds having the following Formula IV:

[0253]

[0254]

[0255] A prodrug, ester, derivative or salt thereof, wherein the substituents are as described herein. In certain embodiments, R 5 In certain embodiments, X, V, and W are CH. In certain embodiments, the compound is N optionally substituted with one or more substituents. 2 -(2,4-morpholinylphenyl)-N 5 -methyl-1,3,4-thiadiazole-2,5-diamine or a salt thereof.

[0256] Pharmaceutical composition

[0257] In certain embodiments, the present disclosure relates to pharmaceutical compositions comprising a compound disclosed herein and a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition is in the form of a pill, capsule, tablet or saline solution buffer.

[0258] In certain embodiments, the pharmaceutically acceptable excipient is selected from carbohydrates, disaccharides, sucrose, lactose, glucose, mannitol, sorbitol, polysaccharides, starch, cellulose, microcrystalline cellulose, cellulose ethers, hydroxypropyl cellulose (HPC), xylitol, sorbitol, maltitol, gelatin, polyvinyl pyrrolidone (PVP), polyethylene glycol (PEG), hydroxypropyl methylcellulose (HPMC), cross-linked sodium carboxymethyl cellulose, calcium hydrogen phosphate, calcium carbonate, stearic acid, magnesium stearate, talc, magnesium carbonate, silicon dioxide, vitamin A, vitamin E, vitamin C, retinyl palmitate, selenium, cysteine, methionine, citric acid and sodium citrate, methylparaben, propylparaben, and combinations thereof.

[0259] The pharmaceutical compositions disclosed herein may be in the form of pharmaceutically acceptable salts, as generally described below. Some preferred but non-limiting examples of suitable pharmaceutically acceptable organic and / or inorganic acids are hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, acetic acid and citric acid, as well as other pharmaceutically acceptable acids known per se (with regard to them, reference is made to the references cited below).

[0260] When the compounds of the present disclosure contain acidic groups and basic groups, the compounds of the present disclosure may also form internal salts, and such compounds are also within the scope of the present disclosure. When the compounds of the present disclosure contain hydrogen-donating heteroatoms (e.g., NH), the present disclosure encompasses salts and / or isomers formed by transferring the hydrogen atoms to basic groups or atoms within the molecule.

[0261] Pharmaceutically acceptable salts of the compounds include acid addition salts and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include acetate, adipate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, cyclamate, edisylate, ethanesulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, hyaluronate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthoate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, toluenesulfonate, trifluoroacetate, and xinofoate. Suitable base salts are formed from bases which form non-toxic salts. Examples include aluminum, arginine, benzathine penicillin, calcium, choline, diethylamine, diethanolamine, glycine, lysine, magnesium, meglumine, ethanolamine, potassium, sodium, tromethamine, and zinc salts. Hemisalts of acids and bases, such as hemisulphate and hemicalcium salts, can also be formed. For a review of suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use, by Stahl and Wermuth (Wiley-VCH, 2002), which is incorporated herein by reference.

[0262] The compounds described herein can be administered in the form of prodrugs. Prodrugs may include covalently bonded carriers that release active parent drugs when administered to mammalian subjects. Prodrugs can be prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved into parent compounds during routine manipulation or in vivo. Prodrugs include, for example, compounds in which hydroxyl groups are bound to any group that cleaves to form free hydroxyl groups when the prodrug is administered to a mammalian subject. Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of alcohol functional groups in compounds. Methods for constructing compounds as prodrugs can be found in Testa and Mayer's book Hydrolysis in Drug and Prodrug Metabolism, Wiley (2006). Typical prodrugs are converted to prodrugs by hydrolases; hydrolysis of amides, lactams, peptides, carboxylates, epoxides, or cleavage of inorganic acid esters to form active metabolites. It is entirely within the general technical scope of the art to prepare ester prodrugs, such as acetyl esters of free hydroxyl groups. It is well known that ester prodrugs are easily degraded in vivo, thereby releasing the corresponding alcohol. See, e.g., Imai, Drug Metab Pharmacokinet. (2006) 21(3): 173-85, entitled "Human carboxylesterase isozymes: catalytic properties and rational drug design."

[0263] The pharmaceutical composition used in the present disclosure generally comprises an effective amount of a compound and a suitable pharmaceutically acceptable carrier. The preparation can be prepared in a manner known per se, which generally comprises mixing at least one compound according to the present disclosure with one or more pharmaceutically acceptable carriers and, if necessary, combining with other pharmaceutically active compounds under sterile conditions where necessary. Reference is made to U.S. Patent No. 6,372,778, U.S. Patent No. 6,369,086, U.S. Patent No. 6,369,087 and U.S. Patent No. 6,372,733 and other references mentioned above, as well as standard handbooks, such as the latest edition of Remington's Pharmaceutical Sciences.

[0264] Typically, for pharmaceutical use, the compounds may be formulated into a pharmaceutical preparation comprising at least one compound and at least one pharmaceutically acceptable carrier, diluent or excipient and / or adjuvant and optionally one or more other pharmaceutically active compounds.

[0265] The pharmaceutical formulations of the present disclosure are preferably in unit dosage form and may be suitably packaged, for example, in boxes, blisters, vials, bottles, sachets, ampoules or any other suitable single-dose or multi-dose retainers or containers (which may be appropriately labeled); optionally accompanied by one or more leaflets containing product information and / or instructions for use. Typically, such unit doses will contain 1 to 1000 mg, and typically 5 to 500 mg, of at least one compound of the present disclosure, for example about 10, 25, 50, 100, 200, 300 or 400 mg per unit dose.

[0266] Compounds can be administered by a variety of routes, including oral, ocular, rectal, transdermal, subcutaneous, intravenous, intramuscular or intranasal routes, depending primarily on the specific formulation used. Compounds will generally be administered in an "effective amount", which means that any amount of compound sufficient to achieve the desired treatment or preventive effect in the subject to which the compound is administered after appropriate administration. Typically, according to the condition to be prevented or treated and the route of administration, the effective amount will generally be between 0.01 and 1000 mg per kg of patient body weight per day, more often between 0.1 and 500 mg per kg of patient body weight per day, such as between 1 and 250 mg, such as about 5, 10, 20, 50, 100, 150, 200 or 250 mg, and can be administered as a single daily dose, divided into one or more daily doses. Amount, route of administration and further treatment regimens can be determined by treating clinicians, depending on factors such as the age, sex and general condition of the patient and the nature and severity of the disease / symptoms to be treated. Reference is made to US Patent No. 6,372,778, US Patent No. 6,369,086, US Patent No. 6,369,087 and US Patent No. 6,372,733 and the other references mentioned above, as well as to standard handbooks, such as the latest edition of Remington's Pharmaceutical Sciences.

[0267] For oral administration forms, the compound can be mixed with suitable additives such as excipients, stabilizers or inert diluents and prepared into suitable administration forms such as tablets, coated tablets, hard capsules, aqueous solutions, alcoholic solutions or oily solutions by conventional methods. Examples of suitable inert carriers are gum arabic, magnesium oxide, magnesium carbonate, potassium phosphate, lactose, glucose or starch, particularly corn starch. In this case, preparation can be carried out as dry granules or wet granules. Suitable oily excipients or solvents are vegetable oils or animal oils, such as sunflower oil or cod liver oil. Solvents suitable for aqueous or alcoholic solutions are water, ethanol, sugar solutions or mixtures thereof. Polyethylene glycol and polypropylene glycol can also be used as further adjuvants for other administration forms. As quick-release tablets, these compositions can contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and / or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.

[0268] When administered by nasal aerosol or inhalation, the composition can be prepared according to well-known techniques in the field of pharmaceutical preparations, and can be prepared as saline solutions using benzyl alcohol or other suitable preservatives, absorption promoters for improving bioavailability, fluorocarbons and / or other solubilizing agents or dispersants known in the art. Pharmaceutical preparations suitable for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the disclosed compounds or their physiologically tolerable salts in pharmaceutically acceptable solvents (e.g., ethanol or water) or mixtures of these solvents. If desired, the preparation may contain other pharmaceutical adjuvants, such as surfactants, emulsifiers and stabilizers and propellants.

[0269] For subcutaneous or intravenous administration, if necessary, the compound is made into a solution, suspension or emulsion together with a common substance such as a solubilizer, an emulsifier or other auxiliary agent. The compound can also be lyophilized and the lyophilized material obtained is used, for example, to produce an injection or infusion preparation. Suitable solvents are, for example, water, physiological saline solution or alcohol (e.g., ethanol, propanol, glycerol), sugar solutions (e.g., glucose or mannitol solutions), or mixtures of the above various solvents. Injectable solutions or suspensions can be prepared according to known techniques using suitable nontoxic, parenterally acceptable diluents or solvents (e.g., mannitol, 1,3-butylene glycol, water, Ringer's solution or isotonic sodium chloride solution), or suitable dispersants or wetting agents and suspending agents (e.g., sterile, mild fixed oils, including synthetic monoglycerides or diglycerides, and fatty acids, including oleic acid).

[0270] When administered rectally in the form of a suppository, the formulation can be prepared by mixing the compound with a suitable non-irritating excipient (such as cocoa butter, synthetic glycerides or polyethylene glycols) which is solid at ordinary temperatures but liquefies and / or dissolves in the rectal cavity to release the drug.

[0271] In certain embodiments, it is expected that these compositions can be sustained-release preparations. Typical sustained-release preparations use enteric coatings. Typically, barriers are applied to oral medications to control where the drug is absorbed in the digestive system. Enteric coatings prevent the drug from being released before reaching the small intestine. Enteric coatings can include polysaccharide polymers such as maltodextrin, xanthan gum, scleroglucan, dextran, starch, alginate, pullulan, hyaluronic acid, chitin, chitosan, etc.; other natural polymers such as proteins (albumin, gelatin, etc.), poly-L-lysine; sodium poly(acrylic acid); poly(hydroxyalkyl methacrylate) (e.g., poly(hydroxyethyl methacrylate)); carboxypolymethylene (e.g., Carbopol TM ); carbomer; polyvinyl pyrrolidone; gums such as guar gum, gum arabic, gum karaya, gum ghatti, locust bean gum, tamarind gum, gellan gum, gum tragacanth, agar, pectin, gluten, etc.; poly(vinyl alcohol); ethylene vinyl alcohol; polyethylene glycol (PEG); and cellulose ethers such as hydroxymethylcellulose (HMC), hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), methylcellulose (MC), ethylcellulose (EC), carboxyethylcellulose (CEC), ethylhydroxyethylcellulose (EHEC), carboxymethylhydroxyethylcellulose (CMHEC), hydroxypropylmethylcellulose (HPMC), hydroxypropylethylcellulose (HPEC) and sodium carboxymethylcellulose (Na CMC); and copolymers and / or (simple) mixtures of any of the above polymers. Some of the above polymers may be further cross-linked by standard techniques.

[0272] The selection of polymer will depend on the property of the active ingredient / medicine used in the composition of the present invention and the required release rate.Especially, the technician will understand that, for example, in the case of HPMC, higher molecular weight will provide the rate at which slower drugs are released from the composition usually.In addition, in the case of HPMC, the different substitution degrees of methoxy and hydroxypropoxy will cause the rate at which drugs are released from the composition to change.In this regard, and as mentioned above, it may be necessary to provide the composition of the present invention in a coating form, wherein the polymer carrier is provided in the form of a blend of two or more polymers of, for example, different molecular weights, to produce a desired or desired specific release profile.

[0273] Microspheres of polylactide, polyglycolide, and their copolymers poly(lactide-co-glycolide) can be used to form a sustained release protein or compound delivery system. Proteins and / or compounds can be embedded in the poly(lactide-co-glycolide) microsphere reservoir by a variety of methods, including forming a water-in-oil emulsion with aqueous protein and an organic solvent-based polymer (emulsion method); forming a solid-in-oil suspension in which the solid protein is dispersed in a solvent-based polymer solution (suspension method); or dissolving the protein in a solvent-based polymer solution (dissolution method). One can attach poly(ethylene glycol) to proteins (PEGylation) to increase the in vivo half-life of circulating therapeutic proteins and reduce the chance of immune response.

[0274] How to use

[0275] The present disclosure relates to asparagine endopeptidase inhibitors for treating or preventing metastasis, tumor growth and / or cancer. In certain embodiments, the present disclosure relates to methods for treating cancer, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a compound disclosed herein. In certain embodiments, the subject is at risk of, exhibits symptoms of, or is diagnosed with breast cancer, prostate cancer, colorectal cancer, gastric cancer, lung cancer, skin cancer, bladder cancer, brain cancer, kidney cancer, endometrial cancer, pancreatic cancer, and thyroid cancer.

[0276] "Cancer" refers to any of the various cell diseases with malignant tumors characterized by cell proliferation. It is not that the diseased cells must actually invade surrounding tissues and metastasize to new body parts. Cancer can involve any tissue of the body, and there are many different forms in each body part. In the case of certain embodiments, "cancer is reduced" can be identified by a variety of diagnostic methods known to those skilled in the art, including but not limited to observing the reduction in the size or number of tumor masses or whether an increase in apoptosis of cancer cells is observed, for example, compared with a control without a sample compound, whether apoptosis of cancer cells observed for the compound increases by more than 5%. It can also be identified whether cancer is reduced by changes in related biomarkers or gene expression profiles, such as PSA for prostate cancer, HER2 for breast cancer or others.

[0277] The cancer to be treated in the context of the present disclosure can be any type of cancer or tumor. These tumors or cancers include, but are not limited to, tumors of hematopoietic and lymphoid tissue or hematopoietic and lymphoid malignancies; tumors that affect the blood, bone marrow, lymph and lymphatic systems. Hematological malignancies can originate from either of the two major blood cell lineages: the myeloid cell lineage and the lymphoid cell lineage. The myeloid cell lineage typically produces granulocytes, erythrocytes, platelets, macrophages and mast cells; the lymphoid cell lineage produces B cells, T cells, NK cells and plasma cells. Lymphomas, lymphocytic leukemias and myelomas are from the lymphoid lineage, while acute and chronic myeloid leukemias, myelodysplastic syndromes and myeloproliferative diseases originate from the myeloid lineage.

[0278] Also contemplated are malignancies located in the colon, abdomen, bones, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testis, ovary, thymus, thyroid), eyes, head and neck, nervous system (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and genitourinary organs, and more specifically childhood acute lymphoblastic leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, adrenocortical carcinoma, adult (original) Adult (primary) hepatocellular carcinoma, adult (primary) liver cancer, adult acute lymphoblastic leukemia, adult acute myeloid leukemia, adult Hodgkin's disease, adult Hodgkin's lymphoma, adult lymphocytic leukemia, adult non-Hodgkin's lymphoma, adult primary liver cancer, adult soft tissue sarcoma, AIDS-related lymphoma, AIDS-related malignancies, anal cancer, astrocytoma, biliary tract cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, renal pelvis and ureter cancer, primary central nervous system lymphoma, central nervous system Systemic lymphoma, cerebellar astrocytoma, brain astrocytoma, cervical cancer, childhood (primary) hepatocellular carcinoma, childhood (primary) liver cancer, childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia, childhood brain stem glioma, childhood cerebellar astrocytoma, childhood brain astrocytoma, childhood extracranial germ cell tumor, childhood Hodgkin's disease, childhood Hodgkin's lymphoma, childhood visual pathway and hypothalamic glioma, childhood lymphoblastic leukemia, childhood medulloblastoma, childhood non-Hodgkin's lymphoma, childhood supratentorial Primitive neuroectodermal and pineal tumors, primary liver cancer in children, rhabdomyosarcoma in children, soft tissue sarcomas in children, visual pathway and hypothalamic gliomas in children, chronic lymphocytic leukemia, chronic myeloid leukemia, colon cancer, cutaneous T-cell lymphoma, endocrine islet cell carcinoma, endometrial cancer, ependymoma, epithelial cancer, esophageal cancer, Ewing's sarcoma and related tumors, exocrine pancreatic cancer, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic biliary tract cancer, eye cancer, female breast cancer, Gaucher's disease, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal tumors, germ cell tumors, gestational trophoblastic tumors, hairy cell leukemia (tricoleukemia), head and neck cancer, hepatocellular carcinoma, Hodgkin's disease, Hodgkin's lymphoma, hypergammaglobulinemia, hypopharyngeal cancer, intestinal cancer, intraocular melanoma, islet cell carcinoma, islet cell pancreatic cancer, Kaposi's sarcomasarcoma), kidney cancer, laryngeal cancer, lip and mouth cancer, liver cancer, lung cancer, lymphoproliferative diseases, macroglobulinemia, male breast cancer, malignant mesothelioma, malignant thymoma, medulloblastoma, melanoma, mesothelioma, occult primary metastatic squamous neck cancer, primary metastatic squamous neck cancer, metastatic squamous neck cancer, multiple myeloma, multiple myeloma / plasmacytoma, myelodysplastic syndrome, myeloid leukemia, myelocytic leukemia, myeloproliferative Physiological diseases, paranasal sinus and sinus cavity cancer, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin lymphoma during pregnancy, non-melanoma skin cancer, non-small cell lung cancer, occult primary metastatic squamous neck cancer, oropharyngeal cancer, malignant fibrous histiocytoma, malignant fibrous osteosarcoma / bone histiocytoma, epithelial ovarian cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, paraproteinemia, purpura, parathyroid cancer, penile cancer, pheochromocytoma, pituitary tumor , plasmacytoma / multiple myeloma, primary central nervous system lymphoma, primary liver cancer, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis and ureteral cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoidosis, sarcoma, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous neck cancer, gastric cancer, pineal and supratentorial primitive neuroectodermal tumors, T-cell lymphoma, testicular cancer, thymoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, transitional cell carcinoma of the renal pelvis and ureter, trophoblastic tumor, renal pelvis and ureteral cell carcinoma, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, visual pathway and hypothalamic gliomas, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor, and any other hyperproliferative disease, as well as tumors located in the systems of the aforementioned organs.

[0279] In certain embodiments, the compounds disclosed herein are combined with another anticancer agent. In certain embodiments, the anticancer agent is selected from abemaciclib, abiraterone acetate, methotrexate, paclitaxel, paclitaxel, acalabrutinib, brentuximab vedotin, ado-trastuzumab bemtansine, aflibercept, afatinib, netupitant, palonosetron, imiquimod, aldesleukin, alectinib, alemtuzumab, pemetrexed disodium disodium), copanlisib, melphalan, brigatinib, chlorambucil, amifostine, aminolevulinic acid, anastrozole, apalutamide, aprepitant, pamidronate disodium, exemestane, nelarabine, arsenic trioxide, ofatumumab, atezolizumab, bevacizumab, avelumab, axicabtagene ciloleucel), axitinib, azacitidine, carmustine, belinostat, bendamustine, inotuzumab ozogamicin, bevacizumab, bexarotene, bicalutamide, bleomycin, blinatumomab, bortezomib, bosutinib, brentuximab vedotin, brigatinib, busulfan, irinotecan, capecitabine, fluorouracil, carboplatin,carfilzomib, ceritinib, daunorubicin, cetuximab, cisplatin, cladribine, cyclophosphamide, clofarabine, cobimetinib, cabozantinib-S-malate, dactinomycin, crizotinib, ifosfamide, ramucirumab, cytarabine, dabrafenib, dacarbazine, decitabine, daratumumab, dasatinib, defibrotide, degarelix, denileukin diftitox, denosumab, dexamethasone, dexrazoxane, dinutuximab, docetaxel, doxorubicin, durvalumab, rasburicase, epirubicin, elotuzumab, oxaliplatin, eltrombopag olamine, enasidenib, enzalutamide, eribulin, vismodegib, erlotinib, etoposide, everolimus, raloxifene, toremifene, panobinostat, fulvestrant, letrozole, filgrastim, fludarabine, flutamide, pralatrexate, obinutuzumab, gefitinib, gemcitabine, gemtuzumab ozogamicin ozogamicin), glucarpidase, goserelin, propranolol, trastuzumab, topotecan,Palbociclib, ibritumomab tiuxetan, ibrutinib, ponatinib, idarubicin, idelalisib, imatinib, talimogenelaherparepvec, ipilimumab, romidepsin, ixabepilone, ixazomib, ruxolitinib, cabazitaxel, palifermin in), pembrolizumab, ribociclib, tisagenlecleucel, lanreotide, lapatinib, olaratumab, lenalidomide, lenvatinib, folinic acid, leuprolide, lomustine, trifluridine, olaparib, vincristine , procarbazine, mechlorethamine, megestrol, trametinib, temozolomide, methylnaltrexone bromide, midostaurin, mitomycin C, mitoxantrone, plerixafor, vinorelbine, necitumumab, neratinib, sorafenib, nilutamide amide), nilotinib, niraparib, nivolumab, tamoxifen, romiplostim, sonidegib, omacetaxine, pegaspargase, ondansetron, osimertinib, panitumumab, pazopanib, interferon α-2b, pertuzumab,Pomalidomide, mercaptopurine, regorafenib, rituximab, rolapitant, rucaparib, siltuximab, sunitinib, thioguanine, temsirolimus, thalidomide, thiotepa, trabectedin, valrubicin, vandetanib, vinblastine, vemurafenib, vorinostat vorinostat, zoledronic acid or a combination thereof, such as cyclophosphamide, methotrexate, 5-fluorouracil (CMF); doxorubicin, cyclophosphamide (AC); nitrogen mustard, vincristine, procarbazine, prednisolone (MOPP); sdriamycin, bleomycin, vinblastine, dacarbazine (ABVD); cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP); rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (RCHOP); bleomycin, etoposide, cisplatin (BEP); epirubicin, cisplatin, 5-fluorouracil (ECF); epirubicin, cisplatin, capecitabine (ECX); methotrexate, vincristine, doxorubicin, cisplatin (MVAC).

[0280] In certain embodiments, the anticancer agent is an anti-PD-1, an anti-CTLA4 antibody, or a combination thereof, such as anti-CTLA4 (e.g., ipilimumab, tremelimumab) and anti-PD1 (e.g., nivizumab, pelotinib, izotuzumab, avelumab, durvalumab). In certain embodiments, the method of administration is performed in a subject with a lymphocyte removal environment. In certain embodiments, lymphodepleting agents (e.g., cyclophosphamide and fludarabine).

[0281] In certain embodiments, the disclosure is expected to use compounds disclosed herein and one or more other anticancer agents to treat or prevent breast cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and trastuzumab and / or lapatinib to treat or prevent breast cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and docetaxel and cyclophosphamide to treat or prevent breast cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and docetaxel, carboplatin and trastuzumab to treat or prevent breast cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and cyclophosphamide, doxorubicin and 5-fluorouracil (5-FU) to treat or prevent breast cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and docetaxel, doxorubicin and cyclophosphamide to treat or prevent breast cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and docetaxel, doxorubicin and cyclophosphamide to treat or prevent breast cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and doxorubicin and cyclophosphamide, followed by paclitaxel or docetaxel to treat or prevent breast cancer. In certain embodiments, the present disclosure contemplates the use of a compound disclosed herein and 5-FU, epirubicin, and cyclophosphamide, followed by docetaxel or paclitaxel to treat or prevent breast cancer.

[0282] In certain embodiments, the disclosure is expected to use compounds disclosed herein and one or more other anticancer agents to treat or prevent prostate cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and leuprolide, goserelin or buserelin to treat or prevent prostate cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and flutamide, bicalutamide, enzalutamide or nilutamide to treat or prevent prostate cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and ketoconazole or aminoglutethimide to treat or prevent prostate cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and abiraterone, bicalutamide, cabazitaxel, bicalutamide, degarelix, denosumab, docetaxel, enzalutamide, cabazitaxel, leuprolide, prednisone, denosumab, sipuleucel-T or radium dichloride 223 and combinations thereof to treat or prevent prostate cancer.

[0283] In certain embodiments, the disclosure is expected to use compounds disclosed herein and one or more other anticancer agents to treat or prevent colon cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and 5-FU, folinic acid or capecitabine or a combination thereof to treat or prevent colon cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and capecitabine and oxaliplatin to treat or prevent colon cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and 5-FU, folinic acid and oxaliplatin to treat or prevent colon cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and folinic acid, 5-FU and irinotecan to treat or prevent colon cancer. In certain embodiments, the disclosure is expected to use compounds disclosed herein and folinic acid, 5-FU, oxaliplatin and irinotecan to treat or prevent colon cancer.

[0284] In certain embodiments, the disclosure contemplates the use of compounds disclosed herein and bevacizumab or cetuximab to treat or prevent colon cancer. In certain embodiments, the disclosure contemplates the use of compounds disclosed herein and 5-FU and folinic acid optionally with bevacizumab to treat or prevent colon cancer. In certain embodiments, the disclosure contemplates the use of compounds disclosed herein and capecitabine optionally with bevacizumab to treat or prevent colon cancer. In certain embodiments, the disclosure contemplates the use of compounds disclosed herein and irinotecan optionally with cetuximab to treat or prevent colon cancer. In certain embodiments, the disclosure contemplates the use of compounds disclosed herein and cetuximab to treat or prevent colon cancer. In certain embodiments, the disclosure contemplates the use of compounds disclosed herein and panitumumab to treat or prevent colon cancer. In certain embodiments, the disclosure contemplates the use of compounds disclosed herein and regorafenib to treat or prevent colon cancer.

[0285] In certain embodiments, the disclosure is expected to use compounds disclosed herein to treat or prevent lung cancer and chemotherapeutics selected from vinorelbine, etoposide, mitomycin C, gemcitabine, irinotecan, pemetrexed, gefitinib, erlotinib, lapatinib, crizotinib and vinca alkaloids or combinations thereof. In certain embodiments, vinca alkaloids are vinblastine, vincristine, vindesine or vinorelbine. In certain embodiments, the disclosure is expected to use compounds disclosed herein to treat or prevent lung cancer and chemotherapeutics are bevacizumab, panitumumab, zalutumumab (zalutumumab), nimotuzumab (nimotuzumab), matuzumab (matuzumab) or cetuximab. In certain embodiments, the disclosure is expected to use compounds disclosed herein and platinum-based agents and / or taxanes (such as paclitaxel and docetaxel) or combinations thereof to treat or prevent lung cancer.

[0286] In certain embodiments, the disclosure is intended to treat or prevent brain cancer, glioblastoma multiforme, oligodendroglioma, primitive neuroectodermal tumor, ependymoma, glioma, including the use of compounds disclosed herein such as 7-morpholinylbenzo [c] [1,2,5] oxadiazole-4-amine or its optionally substituted derivatives or salts to subjects in need. In certain embodiments, the compound is optionally administered in combination with temozolomide, procarbazine, carmustine (BCNU), lomustine (CCNU), vincristine and combinations thereof. In certain embodiments, procarbazine, lomustine (CCNU) and vincristine are combined. In certain embodiments, the compound is optionally administered in combination with irinotecan, cisplatin, carboplatin, methotrexate, etoposide, bleomycin, vinblastine, actinomycin (dactinomycin), cyclophosphamide or ifosfamide.

[0287] In certain embodiments, the present disclosure contemplates combinations of compounds disclosed herein with temozolomide. Treatment of glioblastoma includes chemotherapy during and after radiation therapy.

[0288] In certain embodiments, the present disclosure relates to administering the compositions disclosed herein by convection enhanced delivery (CED) to manage cancer or tumors in the brain. CED is a method of administering a composition by direct infusion into the interstitial space of the brain using a fluid pressure gradient after catheter placement.

[0289] Cancer treatments disclosed herein may be applied as the sole therapy or may involve conventional surgery or radiation therapy or chemotherapy. Such chemotherapy may include one or more of the following classes of anti-tumor agents:

[0290] (i) antiproliferative / antitumor drugs and combinations thereof, such as alkylating agents (e.g. cisplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulfan and nitrosoureas); antimetabolites (e.g. antifolates, such as fluoropyrimidines, e.g. 5-fluorouracil and gemcitabine, tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea); antitumor antibiotics (e.g. anthracyclines, such as doxorubicin, bleomycin, antimitotic agents (e.g., vinca alkaloids such as vincristine, vinblastine, vindesine, and vinorelbine, and taxanes such as paclitaxel and taxotere); and topoisomerase inhibitors (e.g., epipodophyllotoxins such as etoposide and teniposide, amsacrine, topotecan, and camptothecin); and proteasome inhibitors (e.g., bortezomib ); and the drug anegrilide and the pharmaceutical agent interferon alpha;

[0291] (ii) cytostatics, such as antiestrogens (e.g. tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), estrogen receptor downregulators (e.g. fulvestrant), antiandrogens (e.g. bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (e.g. goserelin, leuprolide and buserelin), progestins (e.g. megestrol acetate), aromatase inhibitors (e.g. anastrozole, letrozole, vorazole and exemestane) and 5α-reductase inhibitors such as finasteride;

[0292] (iii) agents that inhibit cancer cell invasion (e.g., metalloproteinase inhibitors, such as marimastat, and inhibitors of urokinase plasminogen activator receptor function);

[0293] (iv) inhibitors of growth factor function, for example, such inhibitors include growth factor antibodies, growth factor receptor antibodies (e.g., anti-Her2 antibody trastuzumab and anti-epidermal growth factor receptor (EGFR) antibody cetuximab), farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine / threonine kinase inhibitors, for example, inhibitors of the epidermal growth factor family, for example, EGFR family tyrosine kinase inhibitors such as: N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib ) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI1033), inhibitors of the platelet-derived growth factor family and inhibitors of the hepatocyte growth factor family, such as inhibitors of phosphatidylinositol 3-kinase (PI3K) and inhibitors of mitogen-activated protein kinase kinase (MEK1 / 2) and inhibitors of protein kinase B (PKB / Akt), inhibitors of the Src tyrosine kinase family and / or the Abelson (Abl) tyrosine kinase family, such as dasatinib (BMS-354825) and imatinib mesylate (Gleevec TM ); and any agent that alters STAT signaling;

[0294] (v) anti-angiogenic agents, such as agents that inhibit the action of vascular endothelial growth factor (e.g., the anti-vascular endothelial growth factor antibody bevacizumab [Avastin TM]) and compounds that act through other mechanisms (e.g., linomide, inhibitors of integrin ocvβ3 function, and angiostatin);

[0295] (vi) Vascular damaging agents, such as Combretastatin A4;

[0296] (vii) antisense therapies, such as those directed against the targets listed above, e.g., anti-RAS antisense therapies; and

[0297] (viii) immunotherapy methods, including, for example, in vitro and in vivo methods for increasing the immunogenicity of the tumor cells tested (e.g., transfection with cytokines such as interleukin 2, interleukin 4, or granulocyte-macrophage colony-stimulating factor), methods for reducing T-cell anergy, methods using transfected immune cells (e.g., cytokine-transfected dendritic cells), methods using cytokine-transfected tumor cell lines, and methods using anti-idiotypic antibodies, as well as the use of the immunomodulatory drugs thalidomide and lenalidomide method.

[0298] Combination Therapy

[00136] It is also contemplated that the disclosed pharmaceutical compositions will be used together with radiation therapy or surgery, either as an alternative to or in addition to a second therapeutic agent or a chemotherapeutic agent.

[0299] In certain embodiments, the disclosure contemplates the use of compounds disclosed herein and leukemia (CLL) chemotherapy regimens to treat or prevent leukemia. Typical chronic lymphocytic leukemia (CLL) chemotherapy regimens include combined chemotherapy using chlorambucil or cyclophosphamide plus corticosteroids such as prednisone or prednisolone. The use of corticosteroids has the additional benefit of suppressing some related autoimmune diseases (e.g., immune hemolytic anemia or immune-mediated thrombocytopenia). In drug-resistant cases, monotherapy with nucleoside drugs (e.g., fludarabine, pentostatin or cladribine) may be successful. Patients may consider allogeneic or autologous bone marrow transplantation. In certain embodiments, the disclosure contemplates the use of compounds disclosed herein in combination with chlorambucil, cyclophosphamide, prednisone, prednisolone, fludarabine, pentostatin and / or cladribine or a combination thereof. The treatment of acute lymphoblastic leukemia typically includes chemotherapy to achieve bone marrow remission. A typical regimen includes prednisone, vincristine, and an anthracycline, L-asparaginase, or cyclophosphamide. Other options include prednisone, L-asparaginase, and vincristine. Consolidation therapy or intensification therapy to eliminate any residual leukemia may include antimetabolites, such as methotrexate and 6-mercaptopurine (6-MP).

[0300] In certain embodiments, the present disclosure contemplates the use of a compound disclosed herein in combination with COP, CHOP, R-CHOP, imatinib, alemtuzumab, vincristine, L-asparaginase or cyclophosphamide, methotrexate and / or 6-mercaptopurine (6-MP) for combined therapy. COP refers to a chemotherapy regimen of cyclophosphamide, vincristine and prednisone or prednisolone and optionally hydroxydaunorubicin (CHOP) and optionally rituximab (R-CHOP) for the treatment of lymphoma.

[0301] In certain embodiments, asparagine endopeptidase inhibitors can be used to treat or prevent neurodegenerative diseases and cognitive disorders, such as Alzheimer's disease. In certain embodiments, the disclosure relates to a pharmaceutical composition comprising an asparagine endopeptidase inhibitor and a pharmaceutically acceptable excipient. In certain embodiments, the disclosure relates to a method for treating or preventing a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition of an asparagine endopeptidase inhibitor disclosed herein.

[0302] In certain embodiments, the subject is at risk for or exhibits symptoms of AD.

[0303] In certain embodiments, the present disclosure contemplates combining the compounds disclosed herein with imaging agents such as florbetapir ( 18 F) and / or in combination with a therapeutic agent associated with treating or ameliorating one or more symptoms of AD.

[0304] In certain embodiments, the present disclosure contemplates administering the compounds disclosed herein in combination with drugs for memory loss, treatments for behavioral changes, treatments for sleep changes.

[0305] In certain embodiments, the present disclosure contemplates administering the compounds disclosed herein in combination with a drug selected from a cholinesterase inhibitor such as donepezil, rivastigmine, galantamine, and tacrine and / or an NMDA receptor blocker such as memantine to treat the cognitive symptoms of Alzheimer's disease (memory loss, confusion, and problems thinking and reasoning).

[0306] In certain embodiments, the present disclosure contemplates administering the compounds disclosed herein in combination with vitamin E.

[0307] In certain embodiments, the present disclosure contemplates administering the compounds disclosed herein in combination with drugs such as anti-irritability agents, antianxiety agents, antipsychotic agents, anti-insomnia agents, and antidepressants.

[0308] In certain embodiments, the present disclosure contemplates administering the compounds disclosed herein in combination with monoclonal antibody vaccines for amyloid, including but not limited to solanuzemab, gantenerumab, and bapineuzumab.

[0309] In certain embodiments, the present disclosure contemplates administering the compounds disclosed herein in combination with an agent for stroke or traumatic brain injury.

[0310] In certain embodiments, the present disclosure contemplates administering the compounds disclosed herein in combination with recombinant tissue plasminogen activator (rtPA).

[0311] In certain embodiments, the compounds disclosed herein can be used to treat a variety of diseases associated with apoptosis, including neurodegenerative disorders, ischemic injury, acquired immunodeficiency syndrome (AIDS), and osteoporosis. Apoptosis is involved in amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, Parkinson's disease, and spinal muscular atrophy. In multiple sclerosis (MS), the death of oligodendrocytes is an important example of glial degeneration through apoptosis.

[0312] In certain embodiments, the compounds disclosed herein can be used to treat Huntington's disease and other neurodegenerative diseases, such as dentatorubral pallidum-Lewy body atrophy (DRPLA), spinocerebellar atrophy type 3 (SCA-3), and spinal bulbar muscular atrophy (SBMA).

[0313] Neuronal apoptosis can also be seen after acute insults such as stroke, trauma, and ischemia. Apoptosis has been observed in striatal and cortical neurons in animal models of stroke.

[0314] experiment

[0315] Various concentrations of compounds were incubated with AEP reaction buffer (50 mM sodium citrate pH 5.5, 0.1% CHAPS, 60 mM Na2HPO4, 1 mM EDTA, final pH 6.0) and the peptide substrate 10 M Cbz-AAN-AMC. The reaction was started after the addition of 50 nM AEP and the formation of fluorescent product was monitored over 15 minutes. IC 50 The value was calculated by the following equation: Fractional enzyme activity = 1 / (1+([I] / IC 50 )), where [I] = inhibitor concentration, and IC 50 = inhibitor concentration producing half maximal activity. Data were analyzed using GraFit version 5.0.11 software package.

[0316] (7-((5-(Methylamino)-1,3,4-thiadiazol-2-yl)amino)-4-morpholinobenzo[c][1,2,5]oxadiazol-5-yl)methanol

[0317]

[0318]

[0319] The compounds disclosed herein can be prepared using the procedures outlined herein by substituting the appropriate starting materials.

[0320] Synthesis of (7-((5-(methylamino)-1,3,4-thiadiazol-2-yl)amino)-4-morpholinobenzo[c][1,2,5]oxadiazol-5-yl)methanol

[0321]

[0322] A mixture of compound 1 (5.00 g, 25.0 mmol) and K2CO3 (690 mg, 5.0 mmol) in ethanol (50 mL) was stirred at room temperature for 10 minutes, then morpholine (3.3 g, 37.6 mmol) was added to the reaction mixture, and stirred overnight at room temperature. The reaction mixture was filtered and the solid filter cake was washed with water (20 mL) and ethanol (40 mL) to obtain compound 2 (6.15 g, 98.0% yield) in the form of a red solid. MS (ESI) m / z 251.1 [M+H] +

[0323] Synthesis of 5-bromo-4-morpholinyl-7-nitrobenzo[c][1,2,5]oxadiazole (3)

[0324]

[0325] To a mixture of compound 2 (6.15 g, 24.6 mmol) in acetonitrile (100 mL) was added NBS (5.25 g, 29.5 mmol) at 0°C. The resulting mixture was stirred at 60°C for 3 hours. After the reaction was complete, the mixture was filtered and the filtrate was concentrated under reduced pressure to give compound 3 (7.30 g, 90% yield) as a red solid; MS (ESI) m / z 328.9, 330.9 [M+H] + .

[0326] Synthesis of 6-bromo-7-morpholinobenzo[c][1,2,5]oxadiazole-4-amine (4)

[0327]

[0328] Concentrated HCl (2 mL) was added to a solution of compound 3 (1.00 g, 3.00 mmol) and Fe (1.70 g, 30.4 mmol) in DCM (10 mL) / methanol (5 mL). The reaction mixture was stirred overnight at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated to give crude compound 4 (820 mg, 90% yield) as a red solid; MS (ESI) m / z 299.0, 301.0 [M+H] + .

[0329] Synthesis of tert-butyl (6-bromo-7-morpholinylbenzo[c][1,2,5]oxadiazol-4-yl)carbamate (5)

[0330]

[0331] To a solution of compound 4 (900 mg, 3.0 mmol) in THF (10 mL) was added (Boc)2O (1.38 g, 6.3 mmol) and DMAP (34 mg, 0.3 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo to provide a residue, and purified by silica gel column chromatography (petroleum ether / EtOAc=10:1) to give compound 5 (1.1 g, 73% yield) as a red solid; MS (ESI) m / z 343.0 [M-156+H] + .

[0332] 7-((tert-Butyloxycarbonyl)amino)-4-morpholinobenzo[c][1,2,5]oxadiazole-5-carboxylic acid methyl ester (6)

[0333]

[0334] Pd(dppf)Cl2 (439 mg, 0.60 mmol) and TEA (1.50 g, 15.9 mmol) were added to a solution of compound 5 (3.00 g, 6.01 mmol) in MeOH (60 mL). The reaction mixture was stirred at 85 ° C and CO (1 MPa) for 16 hours. After cooling to room temperature, the solvent was removed. The residue was purified by column chromatography on a silica gel column (petroleum ether / EtOAc=5:1) to obtain a mixture of compounds 6 and 6a as a red solid (2.30 g, crude product). MS (ESI) m / z 479.2 and 379.1 [M+H] + .

[0335] 7-Amino-4-morpholinobenzo[c][1,2,5]oxadiazole-5-carboxylic acid methyl ester (7)

[0336]

[0337] To a mixture of compound 6 and 6a (2.30 g, crude) in DCM (10 mL) was slowly added TFA (5 mL) at 0°C. The reaction mixture was stirred at room temperature for 2 hours. After removal of the solvent, the residue was purified by preparative HPLC (10-95% CH3CN in H2O, 0.5% ammonia) to give the target compound (1.14 g, 68% yield over 2 steps) as a red solid. MS (ESI) m / z 279.1 [M+H] + .

[0338] 7-((5-((tert-Butyloxycarbonyl)(methyl)amino)-1,3,4-thiadiazol-2-yl)amino)-4-morpholinobenzo[c][1,2,5]oxadiazole-5-carboxylic acid methyl ester (8)

[0339]

[0340] Pd2(dba)3(376mg, 0.40mmol), Xantphos(237mg, 0.40mmol) and Cs2CO3(2.70g, 8.28mmol) were added to a solution of compound 7(1.14g, 4.10mmol) and tert-butyl(5-bromo-1,3,4-thiadiazol-2-yl)(methyl)carbamate(2.40g, 8.16mmol) in dioxane(10mL). The reaction mixture was stirred at 100°C and N2 for 3 hours. The solvent was removed and the residue was purified by column chromatography on a silica gel column (petroleum ether / EtOAc=5:1) to give compound 8(1.12g, crude product) as a red solid. MS(ESI)m / z 492.2[M+H] + .

[0341] Tert-butyl (5-((6-(Hydroxymethyl)-7-morpholinobenzo[c][1,2,5]oxadiazol-4-yl)amino)-1,3,4-thiadiazol-2-yl)(methyl)carbamate (9)

[0342]

[0343] At -78 ° C, DIBAL-H (5.4 mL, 8.12 mmol, 1.5 M toluene solution) was added dropwise to a solution of compound 8 (1.12 g, crude product) in DCM (50 mL). The resulting mixture was stirred at -78 ° C for 1 hour. The reaction was quenched with NH4Cl (aqueous solution), and then the solvent was removed and the residue was purified by column chromatography on a silica gel column (petroleum ether / EtOAc=3:1) to give compound 9 (550 mg, crude product) as a red solid. MS (ESI) m / z 464.2 [M+H] + .

[0344] (7-((5-(Methylamino)-1,3,4-thiadiazol-2-yl)amino)-4-morpholinobenzo[c][1,2,5]oxadiazol-5-yl)methanol

[0345]

[0346] To a solution of compound 9 (550 mg, crude) in DCM (3 mL) was slowly added TFA (1.5 mL) at 0°C. The reaction mixture was stirred at room temperature for 2 hours. After removal of the solvent, the residue was purified by preparative HPLC (10-70% CH3CN in H2O, 0.5% ammonia) to give the target compound (125 mg, 8% yield over 3 steps) as a yellow solid. 1 H NMR (DMSO-d6, 400MHz): δ (ppm) 9.67 (brs, 1H), 8.10 (s, 1H), 5.47 (brs, 1H), 4.69 (s, 2H), 3.77-3.75 (m, 4H), 3.69 (s, 3H), 3.15-3.13 (m, 4H). MS(ESI)m / z 364.1[M+H] + .

[0347] Tert-butyl (6-cyano-7-morpholinobenzo[c][1,2,5]oxadiazol-4-yl)carbamate (10)

[0348]

[0349] Zn(CN)2(1.40g, 12.0mmol), dppf(665mg, 1.20mmol) and Pd2(dba)3(550mg, 0.60mmol) were added to a solution of compound 5(3.00g, 6.01mmol) in NMP(10mL). The reaction mixture was stirred at 100°C for 3 hours under N2 protection. After cooling to room temperature, EtOAc and water were added. The separated organic layer was concentrated and the residue was purified by chromatography on a silica gel column (petroleum ether / EtOAc=3:1) to give compound 6(1.93g, 72% yield) as a red solid. MS(M-100+H + )m / z 346.1.

[0350] 7-Amino-4-morpholinobenzo[c][1,2,5]oxadiazole-5-carbonitrile (11)

[0351]

[0352] To a solution of compound 10 (1.93 g, 4.33 mmol) in DCM (4 mL) was slowly added TFA (2 mL) at 0°C. The reaction mixture was stirred at room temperature for 2 hours. After removal of the solvent, the residue was purified by preparative HPLC (10-70% CH3CN in H2O, 0.5% ammonia) to give the target compound (980 mg, 92% yield) as a red solid. MS (ESI) m / z 246.1 [M+H] +

[0353] 7-((5-(Methylamino)-1,3,4-thiadiazol-2-yl)amino)-4-morpholinobenzo[c][1,2,5]oxadiazole-5-carbonitrile

[0354]

[0355] A mixture of compound 7 (500 mg, 2.0 mmol) and 5-bromo-N-methyl-1,3,4-thiadiazol-2-amine 11 (786 mg, 2.0 mmol), PTSA (422 mg, 2.5 mmol) in NMP (5 mL) was stirred at 150° C. under microwave irradiation for 8 hours. The reaction mixture was directly purified by preparative HPLC (10-95 CH 3 CN in water) to give the desired product (106 mg, 14% yield) as a red solid. 1 H NMR (DMSO-d6, 400MHz): δ (ppm) 10.56 (brs, 1H), 8.07 (s, 1H), 7.20-7.17 (m, 1H), 3.80-3.72 (s, 8H), 2.83 (d, J=4.4Hz, 3H). MS(ESI)m / z 359.1[M+H] + .

[0356] N 2 -Methyl-N 5 Synthesis of -(7-morpholinobenzo[c][1,2,5]oxadiazol-4-yl)-1,3,4-thiadiazole-2,5-diamine

[0357]

[0358] At room temperature and Ar, to a mixture of compound B-1 (3 g, 15 mmol) and morpholine-3-one (1.8 g, 18 mmol) in anhydrous 1,4-dioxane (90 mL) was added Cs2CO3 (9.72 g, 30 mmol), XantPhos (868 mg, 1.5 mmol) and Pd(OAc)2 (337 mg, 1.5 mmol). The reaction was stirred at 70 ° C and Ar for 3 hours. LC-MS showed that part B-1 remained and the desired product was formed as the main product. The cooled reaction mixture was filtered and the filter cake was washed with DCM. The combined filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography (eluent: 6: 1 to 1: 1 PE / EtOAc) to give the desired product as a black solid (1.3 g, yield: 20%, by 1 H NMR confirmed). 1 H NMR (400MHz, CDCl3) δ8.55 (d, J=8.0Hz, 1H), 7.88 (d, J=8.0Hz, 1H), 4.49 (s, 2H), 4.28 (t, J=5.0Hz, 2H), 4.17 (t, J=4.8Hz, 2H).

[0359] To a stirred mixture of compound L-1 (1.3 g, 4.9 mmol) in DCM / MeOH (20 mL / 4 mL) was added Fe (1.37 g, 24.6 mmol) and concentrated HCl (3 mL). The reaction mixture was stirred at room temperature for 2 hours. TLC (PE: EA = 1: 1) showed that the reaction was complete. The reaction mixture was basified with aqueous Na2CO3 until pH was equal to 8. The resulting product was extracted with DCM. The combined organic extracts were concentrated in vacuo. The residue was purified by silica gel chromatography (eluent: 2: 1 to 1: 3 PE: EtOAc) to give the desired L-2 (1 g, yield: 88%, by 1 H NMR and LC-MS confirmed). LC-MS purity: 83% @ 254 nm; [M+H] + =235.1, RT=0.90min. 1 H NMR (400MHz, DMSO-d6) δ7.28 (d, J=7.6Hz, 1H), 6.72 (s, 2H), 6.29 (d, J=7.6Hz, 1H), 4.24 (s, 2H), 4.00 (t, J=5.0Hz, 4H), 3.73 (t, J=4.8Hz, 4H).

[0360]

[0361] To a mixture of compound L-2 (1.0 g, 4.27 mmol) and tert-butyl (5-bromo-1,3,4-thiadiazol-2-yl)(methyl)carbamate (1.88 g, 6.4 mmol) in anhydrous 1,4-dioxane (100 mL) was added CsCO (2.77 g, 8.45 mmol), XantPhos (247 mg, 0.47 mmol) and Pd(dba) (391 mg, 0.427 mmol) at room temperature under Ar. The reaction was stirred at 100° C. under Ar for 3 hours.

[0362] TLC (PE: EA = 1: 1) showed that the reaction was complete. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with DCM. The combined filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography (eluent: 5: 1 to 1: 1 PE: EtOAc) to obtain the impure desired product (600 mg, yield: about 31%) as a red solid.

[0363]

[0364] To a solution of L-3 (600 mg, 1.34 mmol) in DCM (40 mL) was added TFA (3.04 g, 13.4 mmol). The reaction mixture was stirred at room temperature for 2 hours. TLC (PE: EA = 1: 2) showed that the reaction was complete. The reaction mixture was washed with a NaHCO3 aqueous solution and evaporated in vacuo. The residue was purified by preparative HPLC to give the desired product (90 mg, yield: 20%, by 1 H NMR, HPLC and LC-MS confirmed). HPLC purity: 99% @ 254nm; 97% @ 214nm. LC-MS: [M+H] + =348.2, RT=0.90min. 1 H NMR (400MHz, DMSO-d6) δ10.84 (s, 1H), 8.05 (s, 1H), 7.53 (d, J=7.2Hz, 1H), 7.1 9 (s, 1H), 4.03 (t, J=4.8Hz, 4H), 3.81 (t, J=4.6Hz, 4H), 2.84 (t, J=4.8Hz, 3H).

[0365] N 2 -(5-chloro-7-morpholinylbenzo[c][1,2,5]oxadiazol-4-yl)-N 5 -Synthesis of methyl-1,3,4-thiadiazole-2,5-diamine

[0366]

[0367] A solution of compound B-1 (3.5 g, 17.5 mmol), morpholine (3.0 g, 34.5 mmol) and Cs2CO3 (17.0 g, 52.1 mmol) in MeCN (15 mL) was stirred at room temperature for 2 hours. TLC showed that the reaction was complete. EtOAc (500 mL) and water (200 mL) were added to the reaction mixture, and a red solid precipitated. The mixture was filtered. The filter cake was collected and dried to obtain the first portion of the desired product. The organic layer of the filtrate was separated, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to obtain the second portion of the desired product (4.4 g in total, yield: about 100%, by 1 H NMR confirmed). 1 H NMR (400MHz, CDCl3) δ 8.46 (d, J=8.8Hz, 1H), 6.34 (d, J=8.8Hz, 1H), 4.09 (t, J=4.8Hz, 2H), 3.97 (t, J=4.8Hz, 2H).

[0368]

[0369] To a stirred mixture of compound B-2 (4.7 g, 18.8 mmol) in DCM (370 mL) and MeOH (180 mL) was added concentrated HCl (36.5 wt %, 19 mL) and Fe (8.0 g, 142 mmol) at room temperature. The resulting mixture was stirred at room temperature for 30 minutes. Saturated aqueous NaHCO3 was added to the reaction mixture until the pH was equal to 8. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to give the desired product (4.0 g, yield: 97%, by 1 HNMR and LC-MS confirmed). LC-MS: [M+H] + =221.4, RT=1.60min. 1 H NMR (400MHz, DMSO-d6) δ6.49 (d, J=8.0Hz, 1H), 6.26 (d, J=7.6Hz, 1H), 5.76 (brs, 2H), 3.78 (t, J=4.6Hz, 4H), 3.17 (t, J=4.4Hz, 4H).

[0370]

[0371] A mixture of B-3 (1.0 g, 4.5 mmol), (5-bromo-1,3,4-thiadiazol-2-yl)(methyl)carbamic acid tert-butyl ester (1.5 g, 5.1 mmol) and TsOHH2O (960 mg, 5.0 mmol) in i-PrOH (10 mL) was stirred for 5 hours at 120 ° C under microwave irradiation. Saturated NaHCO3 aqueous solution was added to the cooled reaction mixture until the pH was equal to 8. DCM (200 mL) was added and the mixture was stirred for 10 minutes. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by reverse phase chromatography to obtain the impure desired product (650 mg, yield: 43%, confirmed by LC-MS) as a brown solid. LC-MS purity: 68% @ 254 nm. LC-MS: [M+H] + =334.1, RT=1.34min.

[0372]

[0373] At 0 ° C, SO2Cl2 (1.6 g, 12 mmol) was added to a stirred solution of compound B-4a (400 mg, 1.2 mmol) in toluene (10 mL). The reaction was stirred at 0 ° C for 30 minutes. LC-MS showed that the reaction was complete and the desired product was formed along with a large amount of by-products. PE was added to the reaction mixture, and the precipitated yellow solid was collected by filtration. The yellow solid (low purity) was purified by preparative HPLC to give the desired product as a brown solid (9.4 mg, placed in a vial, yield: 2.1%, by 1 H NMR, HPLC and LC-MS confirmed). HPLC purity: 91% @ 254nm; 91% @ 214nm. LC-MS: [M+H] + =368.0, RT=5.14min. 1H NMR (400MHz, DMSO-d6) δ 8.14 (s, 1H), 7.21 (d, J=4.4Hz, 1H), 3.76 (t, J=4.4Hz, 4H), 3.24 (t, J=4.6Hz, 4H), 2.84 (d, J=4.8Hz, 3H).

[0374] N2-methyl-N5-(5-methyl-7-morpholinobenzo[c][1,2,5]oxadiazol-4-yl)-1,3,4-thiadiazole-2,5-diamine

[0375]

[0376] At 0 ° C, to a stirred solution of compound B-3 (500 mg, 2.3 mmol) in MeCN (10 mL) was added pyridinium tribromide (950 mg, 2.95 mmol). The reaction was stirred at 0 ° C for 30 minutes. LC-MS showed that the reaction was complete. Water (100 mL) and ethyl acetate (300 mL) were added to the reaction mixture. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated to obtain the crude desired product, which was purified by reverse phase chromatography to obtain the desired product as a red solid (400 mg, yield: 58%, by 1 H NMR and LC-MS confirmed).

[0377]

[0378] A mixture of compound C-1 (370 mg, 1.2 mmol), methylboronic acid (450 mg, 7.4 mmol), K2CO3 (510 mg, 3.7 mmol) and Pd(PPh3)4 (140 mg, 0.12 mmol) in DMF (12 mL) was stirred at 120°C under argon overnight. The cooled reaction mixture was directly purified by reverse phase chromatography to give the desired product (150 mg, yield: 53%, by 1 1H NMR confirmation) (Note: the position of the methyl group was determined by 2D NMR). 1H NMR (400 MHz, CDCl3) δ 6.25 (s, 1H), 4.10 (brs, 2H), 3.93 (t, J=4.6 Hz, 4H), 3.33 (s, 4H), 2.18 (s, 3H).

[0379]

[0380] A solution of compound C-2 (130 mg, 0.56 mmol), (5-bromo-1,3,4-thiadiazol-2-yl)(methyl)carbamic acid tert-butyl ester (250 mg, 1.83 mmol) and TsOH·H2O (160 mg, 0.83 mmol) was stirred at 120°C under microwave irradiation for 5 hours. TLC showed that a large amount of starting material remained. The cooled reaction mixture was purified by preparative TLC to obtain the desired product (20 mg, purity: 80%), which was further purified by preparative HPLC to obtain the desired product (5.0 mg, placed in a vial, yield: 2.6%, by 1 H NMR, HPLC and LC-MS confirmation).

[0381] HPLC purity: 98%@254nm; 95%@214nm. LC-MS: [M+H] + =348.1, RT=4.04min.1 HNMR(400MHz,DMSO-d6)δ8.93(brs,1H),6.90(d,J=4.8Hz,1H),6.52(s,1H),3.82(t,J=4.4Hz,4H),3.47(t,J=4.4Hz,4H),2.75,2.74(s X 2,3H),2.25(s,3H)。

Claims

1. A compound having the following formula I: or a salt thereof, wherein X is O; R 1 yes Q is O; R 2 is hydrogen or a methyl group substituted by a hydroxy group; R 3 It is hydrogen; R 4 is an amino group substituted by a 1,3,4-thiadiazol-2-yl group, wherein the 1,3,4-thiadiazol-2-yl group is substituted by one or more R 40 replace; R 40 Selected from amino, thiol, wherein R 40 Optionally, one or more identical or different R 41 replace; R 41 Selected from methyl, ethyl, propyl.

2. (7-((5-(Methylamino)-1,3,4-thiadiazol-2-yl)amino)-4-morpholinobenzo[c][1,2,5]oxadiazol-5-yl)methanol or a salt thereof.

3. The compound according to claim 1, wherein the compound is N2-methyl-N5-(7-morpholinobenzo[c][1,2,5]oxadiazol-4-yl)-1,3,4-thiadiazole-2,5-diamine or a salt thereof; or 5-((7-morpholinylbenzo[c][1,2,5]oxadiazol-4-yl)amino)-1,3,4-thiadiazole-2-thiol or a salt thereof.

4. The following compounds and their salts: 。 5. A pharmaceutical composition comprising the compound according to any one of claims 1 to 4 and a pharmaceutically acceptable excipient.

6. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a gel or a cream.

7. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is in the form of a gel capsule.

8. The pharmaceutical composition of claim 5 in the form of a sterile pH buffered saline solution.

9. The pharmaceutical composition of claim 5 in the form of a sterile pH buffered saline solution comprising a sugar.

10. The pharmaceutical composition of claim 5 in the form of saline phosphate buffer at a pH of 6 to 10.

11. The pharmaceutical composition of claim 5 in the form of saline phosphate buffer at a pH of 6 to 10, comprising a sugar.

12. The pharmaceutical composition of claim 5 in the form of an isotonic phosphate buffered saline solution.

13. The pharmaceutical composition of claim 5 in the form of an isotonic phosphate buffered saline solution comprising a sugar.

14. The pharmaceutical composition of any one of claims 9, 11 and 13, wherein the sugar is a polysaccharide.

15. The pharmaceutical composition according to claim 5, which is in a solid form coated with an enteric coating.

16. The pharmaceutical composition of claim 15, wherein the enteric coating comprises methyl acrylate-methacrylic acid copolymer, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, methyl methacrylate-methacrylic acid copolymer, or a combination thereof.

17. The pharmaceutical composition of claim 5, wherein the pharmaceutically acceptable excipient is selected from lactose, sucrose, mannitol, triethyl citrate, dextrose, cellulose, methylcellulose, ethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose, polyvinyl N-pyrrolidone, crospovidone, povidone, copolymers of methyl acrylate and ethyl acrylate, polyethylene glycol, sorbitan fatty acid esters, lauryl sulfate, gelatin, glycerol, monoolein, silicon dioxide, titanium dioxide, talc, carnauba wax, stearic acid, sorbic acid, magnesium stearate, calcium stearate, castor oil, mineral oil, calcium phosphate, starch, carboxymethyl starch ether, iron oxide, triacetin, and gum arabic.

18. The pharmaceutical composition of claim 5, wherein the pharmaceutically acceptable excipient is selected from corn starch.

19. Use of the compound according to any one of claims 1 to 4 for preparing a medicament for treating breast cancer, prostate cancer, colon cancer, rectal cancer, gastric cancer or ovarian cancer.

20. Use of the compound according to any one of claims 1 to 4 for preparing a medicament for treating cognitive disorders, wherein the cognitive disorders are Alzheimer's disease, Parkinson's disease or multiple sclerosis.

21. Use of the pharmaceutical composition according to claim 5 for preparing a drug for treating breast cancer, prostate cancer, colon cancer, rectal cancer, gastric cancer or ovarian cancer.

22. Use of the pharmaceutical composition according to claim 5 for preparing a medicament for treating cognitive disorders, wherein the cognitive disorders are Alzheimer's disease, Parkinson's disease or multiple sclerosis.